News

Immunicum CEO Jamal El-Mosleh said: "We are pleased with the positive news from the Chinese Patent Office, SIPO, which will further strengthen the protection for our main product.

The JV will invest in a new company to be called Imutex. It will boost hVIVO’s commercial flu portfolio and expand its operations into mosquito-borne diseases, with the

The agency’s specific action date is not provided but is expected to happen before the end of this year. Lundbeck received a complete response letter in October 2014

Genomics is the study of the genome, a double string of DNA which features all the genes required to make and operate an organism. The company established collaborations

174 patients with moderately to severely active Crohn’s disease were enrolled in FITZROY, a double-blind, placebo-controlled Phase 2 study. Patients recruited were either anti-TNF naïve or anti-TNF failures.

Discovered by BioMarin, BMN 250 is being studied in a multicenter, international clinical trial evaluating safety and tolerability, as well as cognitive function of patients with MPS IIIB

Exquiron is a leading specialist Contract Research Organization dedicated to early phase drug discovery solutions. Located near Basel, Switzerland, Exquiron offers industry leading expertise in assay development for

Fibrocell’s azficel-T has the potential to address the underlying cause of chronic dysphonia by using the patient’s own cells for localized treatment of the scarred vocal cords to

"We have now determined the Phase II dose and monotherapy regimen of L-DOS47 for patients that have limited treatment options in our LDOS002 study," said Mr. Steve Demas,